Evidence map›Paper›PMID 40746849›Full record

ArticleBiochemistry and biophysics reports2025

Mechanism of SC targeting RhoA regulation and its potential value in gastric cancer therapy.

Haixiu Ma, Ping Jiang, Ronghua Ma, Jing Zhao, Qi Wang, Yonghua Xing, Chengzhu Cao, Zhanhai Su

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Haixiu MaResearch Center for High Altitude Medicine, Key Laboratory for High Altitude Medicine, Ministry of Education, Qinghai University, 16# Kunlun Road, Xining, 810016, Qinghai, China.
Ping JiangDepartment of Basic Medicine Science, Qinghai University Medical College, Xining, 810001,Qinghai, China.
Ronghua MaResearch Center for High Altitude Medicine, Key Laboratory for High Altitude Medicine, Ministry of Education, Qinghai University, 16# Kunlun Road, Xining, 810016, Qinghai, China.
Jing ZhaoResearch Center for High Altitude Medicine, Key Laboratory for High Altitude Medicine, Ministry of Education, Qinghai University, 16# Kunlun Road, Xining, 810016, Qinghai, China.
Qi WangResearch Center for High Altitude Medicine, Key Laboratory for High Altitude Medicine, Ministry of Education, Qinghai University, 16# Kunlun Road, Xining, 810016, Qinghai, China.
Yonghua XingDepartment of Basic Medicine Science, Qinghai University Medical College, Xining, 810001,Qinghai, China.
Chengzhu CaoDepartment of Basic Medicine Science, Qinghai University Medical College, Xining, 810001,Qinghai, China.
Zhanhai SuDepartment of Basic Medicine Science, Qinghai University Medical College, Xining, 810001,Qinghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RhoA drives the malignant progression of gastric cancer through cytoskeletal remodeling and the regulation of epithelial-mesenchymal transition (EMT). Here, we identified a novel small-molecule inhibitor, (E)-1,9-bis(3,4-dihydroxyphenyl)non-3-en-5-one (SC), targeting RhoA through molecular docking and surface plasmon resonance (SPR) validation. SPR kinetics revealed high-affinity binding (KD = 1.588 μM) with rapid association (ka = 2.769 × 10

Indexed as

Drug discoveryDual actionEMTNatural productRhoA inhibitor

Identifiers

PMID40746849
PMCPMC12311952

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.